Business
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on deve
About this update from Instil Bio, Inc.
[{"type":"image","alt":"Instil Bio","displaySize":"","headline":null,"caption":"Instil Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/38MAPe55bTDD07xl6tQzbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b","width":300,"height":157}},"lazy":false},{"type":"text","content":"Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025","length":171,"tagName":"p"},{"type":"text","content":"Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals","length":185,"tagName":"p"},{"type":"text","content":"DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2025 financial results and provided a corporate update.","length":268,"tagName":"p"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ImmuneOnco’s Phase 1b/2 trial of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC in China is ongoing and ImmuneOnco anticipates initial clinical data from first-line NSCLC patients in 2H 2025.","length":206,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":206,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated to commence before the end of 2025: Instil anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for 1L NSCLC patients before the end of 2025, assuming the necessary regulatory approvals are obtained.","length":341,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":341,"olType":false},{"type":"text","content":"First Quarter 2025 Financial and Operating Results:","length":51,"tagName":"p"},{"type":"text","content":"As of March 31, 2025, Ins...